413 related articles for article (PubMed ID: 16179542)
1. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70.
Mandel S; Grunblatt E; Riederer P; Amariglio N; Jacob-Hirsch J; Rechavi G; Youdim MB
Ann N Y Acad Sci; 2005 Aug; 1053():356-75. PubMed ID: 16179542
[TBL] [Abstract][Full Text] [Related]
2. Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra.
Grünblatt E; Ruder J; Monoranu CM; Riederer P; Youdim MB; Mandel SA
Neurotox Res; 2018 Apr; 33(3):560-568. PubMed ID: 29218503
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes.
Grünblatt E; Mandel S; Jacob-Hirsch J; Zeligson S; Amariglo N; Rechavi G; Li J; Ravid R; Roggendorf W; Riederer P; Youdim MB
J Neural Transm (Vienna); 2004 Dec; 111(12):1543-73. PubMed ID: 15455214
[TBL] [Abstract][Full Text] [Related]
4. Ubiquitin-proteasome system and Parkinson's disease.
Olanow CW; McNaught KS
Mov Disord; 2006 Nov; 21(11):1806-23. PubMed ID: 16972273
[TBL] [Abstract][Full Text] [Related]
5. Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease.
McNaught KS; Olanow CW
Neurobiol Aging; 2006 Apr; 27(4):530-45. PubMed ID: 16207501
[TBL] [Abstract][Full Text] [Related]
6. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.
Lee FK; Wong AK; Lee YW; Wan OW; Chan HY; Chung KK
J Neurochem; 2009 Jul; 110(1):208-19. PubMed ID: 19457126
[TBL] [Abstract][Full Text] [Related]
7. Heredity in Parkinson's disease: new findings.
Lev N; Melamed E
Isr Med Assoc J; 2001 Jun; 3(6):435-8. PubMed ID: 11433638
[TBL] [Abstract][Full Text] [Related]
8. Gene and protein signatures in sporadic Parkinson's disease and a novel genetic model of PD.
Mandel SA; Fishman T; Youdim MB
Parkinsonism Relat Disord; 2007; 13 Suppl 3():S242-7. PubMed ID: 18267243
[TBL] [Abstract][Full Text] [Related]
9. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling in progressively MPTP-lesioned macaques reveals molecular pathways associated with sporadic Parkinson's disease.
Ohnuki T; Nakamura A; Okuyama S; Nakamura S
Brain Res; 2010 Jul; 1346():26-42. PubMed ID: 20513370
[TBL] [Abstract][Full Text] [Related]
11. Modeling sporadic Parkinson's disease by silencing the ubiquitin E3 ligase component, SKP1A.
Mandel SA; Fishman-Jacob T; Youdim MB
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S148-51. PubMed ID: 20082978
[TBL] [Abstract][Full Text] [Related]
12. A sporadic Parkinson disease model via silencing of the ubiquitin-proteasome/E3 ligase component SKP1A.
Fishman-Jacob T; Reznichenko L; Youdim MB; Mandel SA
J Biol Chem; 2009 Nov; 284(47):32835-45. PubMed ID: 19748892
[TBL] [Abstract][Full Text] [Related]
13. Psychotropics regulate Skp1a, Aldh1a1, and Hspa8 transcription--potential to delay Parkinson's disease.
Lauterbach EC
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():236-9. PubMed ID: 23046827
[TBL] [Abstract][Full Text] [Related]
14. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases.
Ross CA; Pickart CM
Trends Cell Biol; 2004 Dec; 14(12):703-11. PubMed ID: 15564047
[TBL] [Abstract][Full Text] [Related]
15. D-Serine exposure resulted in gene expression changes indicative of activation of fibrogenic pathways and down-regulation of energy metabolism and oxidative stress response.
Soto A; DelRaso NJ; Schlager JJ; Chan VT
Toxicology; 2008 Jan; 243(1-2):177-92. PubMed ID: 18061331
[TBL] [Abstract][Full Text] [Related]
16. The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease.
McNaught KS; Jnobaptiste R; Jackson T; Jengelley TA
Synapse; 2010 Mar; 64(3):241-50. PubMed ID: 19924695
[TBL] [Abstract][Full Text] [Related]
17. Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration.
Zhu W; Li X; Xie W; Luo F; Kaur D; Andersen JK; Jankovic J; Le W
Neurobiol Dis; 2010 Feb; 37(2):307-13. PubMed ID: 19818853
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
Xie W; Li X; Li C; Zhu W; Jankovic J; Le W
J Neurochem; 2010 Oct; 115(1):188-99. PubMed ID: 20649845
[TBL] [Abstract][Full Text] [Related]
19. Genomic aspects of sporadic Parkinson's disease.
Riederer P; Youdim MB; Mandel S; Gerlach M; Grünblatt E
Parkinsonism Relat Disord; 2008; 14 Suppl 2():S88-91. PubMed ID: 18585078
[TBL] [Abstract][Full Text] [Related]
20. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
